PPARA and Hyperglycemia: In studies conducted in our laboratory, we observed that pharmacological preconditioning with the peroxisomal proliferator-activated receptor-alpha (PPARα) agonist fenofibrate (feno) improves cell viability and favors an antioxidant environment that contributes to preserve cardiac ultrastructure under conditions of hyperglycemia, hypoxia/reoxygenation (H/R), or both [8].